These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33771555)

  • 1. Immunotherapy in treatment of leishmaniasis.
    Akbari M; Oryan A; Hatam G
    Immunol Lett; 2021 May; 233():80-86. PubMed ID: 33771555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature.
    Okwor I; Uzonna JE
    Immunotherapy; 2009 Sep; 1(5):765-76. PubMed ID: 20636022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmaniasis and various immunotherapeutic approaches.
    Taslimi Y; Zahedifard F; Rafati S
    Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research.
    Elmahallawy EK; Alkhaldi AAM; Saleh AA
    Biomed Pharmacother; 2021 Jul; 139():111671. PubMed ID: 33957562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
    Dayakar A; Chandrasekaran S; Kuchipudi SV; Kalangi SK
    Front Immunol; 2019; 10():670. PubMed ID: 31024534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunopathogenesis of Leishmania infections].
    Yurdakul P
    Mikrobiyol Bul; 2005 Jul; 39(3):363-81. PubMed ID: 16358498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control.
    Zahedifard F; Rafati S
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):461-469. PubMed ID: 29889579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian host defense peptides and their implication on combating Leishmania infection.
    Abdossamadi Z; Seyed N; Rafati S
    Cell Immunol; 2016 Nov; 309():23-31. PubMed ID: 27729107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targets for immunochemotherapy in leishmaniasis.
    Mukhopadhyay D; Saha P; Chatterjee M
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):261-4. PubMed ID: 22397558
    [No Abstract]   [Full Text] [Related]  

  • 10. Three decades of clinical trials on immunotherapy for human leishmaniases: a systematic review and meta-analysis.
    Mota CA; Oyama J; Souza Terron Monich M; Brustolin AÁ; Perez de Souza JV; Murase LS; Ghiraldi Lopes LD; Silva Santos TD; Vieira Teixeira JJ; Verzignassi Silveira TG
    Immunotherapy; 2021 Jun; 13(8):693-721. PubMed ID: 33853344
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic vaccines for leishmaniasis.
    Khamesipour A
    Expert Opin Biol Ther; 2014 Nov; 14(11):1641-9. PubMed ID: 25077737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to visceral leishmaniasis: implications for immunotherapy.
    Khadem F; Uzonna JE
    Future Microbiol; 2014; 9(7):901-15. PubMed ID: 25156379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for leishmaniasis.
    Pradhan S; Schwartz RA; Patil A; Grabbe S; Goldust M
    Clin Exp Dermatol; 2022 Mar; 47(3):516-521. PubMed ID: 34480806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present status of antileishmanial vaccines.
    Ghosh M; Bandyopadhyay S
    Mol Cell Biochem; 2003 Nov; 253(1-2):199-205. PubMed ID: 14619970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKT cells in leishmaniasis.
    Zamora-Chimal J; Hernández-Ruiz J; Becker I
    Immunobiology; 2017 Apr; 222(4):641-646. PubMed ID: 28012583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
    Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
    Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.
    Musa AM; Noazin S; Khalil EA; Modabber F
    Trans R Soc Trop Med Hyg; 2010 Jan; 104(1):1-2. PubMed ID: 19712953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
    Shakya N; Sane SA; Vishwakarma P; Gupta S
    Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and perspectives of the immunotherapy of leishmaniasis.
    El-On J
    Isr Med Assoc J; 2009 Oct; 11(10):623-8. PubMed ID: 20077951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.